Paper39467628
Suppressing Expression of SERPINE1/PAI1 Through Activation of GPER1 Reduces Progression of Vulvar Carcinoma.
Doelker T and 2 others. Cancer Genomics Proteomics, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Suppressing Expression of SERPINE1/PAI1 Through Activation of GPER1 Reduces Progression of Vulvar Carcinoma. Papers, record 39467628. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39467628
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Suppressing Expression of SERPINE1/PAI1 Through Activation of GPER1 Reduces Progression of Vulvar Carcinoma.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, G-Protein-Coupled | Major topic |
| Receptors, Estrogen | Major topic |
| Plasminogen Activator Inhibitor 1 | Major topic |
| Vulvar Neoplasms | Major topic |
| Cell Proliferation | Major topic |
| Disease Progression | Major topic |
| Cell Movement | Major topic |
| Humans | |
| Female | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26527320 | Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. | Oncotarget | 2016 | https://conductscience.org/library/papers/26527320 | PubMed |
| 2 | 35119068 | The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer. | Clin Sci (Lond) | 2022 | https://conductscience.org/library/papers/35119068 | PubMed |
| 3 | 9701244 | Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. | Nat Med | 1998 | https://conductscience.org/library/papers/9701244 | PubMed |
| 4 | 37762008 | Activation of G-Protein-Coupled Estrogen Receptor 1 (GPER1) Reduces Progression of Vulvar Carcinoma Cells. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37762008 | PubMed |
| 5 | 31611744 | Estrogen receptor subtype agonist activation in human cutaneous squamous cell carcinoma cells modulates expression of CD55 and Cyclin D1. | EXCLI J | 2019 | https://conductscience.org/library/papers/31611744 | PubMed |
| 6 | 25386620 | Functional stability of plasminogen activator inhibitor-1. | ScientificWorldJournal | 2014 | https://conductscience.org/library/papers/25386620 | PubMed |
| 7 | 28258163 | G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly. | Mol Cancer Ther | 2017 | https://conductscience.org/library/papers/28258163 | PubMed |
| 8 | 29887999 | Adipose Tissue-Secreted Factors Alter Bladder Cancer Cell Migration. | J Obes | 2018 | https://conductscience.org/library/papers/29887999 | PubMed |
| 9 | 33117280 | Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation. | Front Endocrinol (Lausanne) | 2020 | https://conductscience.org/library/papers/33117280 | PubMed |
| 10 | 23988000 | Serpins for diagnosis and therapy in cancer. | Cardiovasc Hematol Disord Drug Targets | 2013 | https://conductscience.org/library/papers/23988000 | PubMed |
| 11 | 15149846 | Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. | Exp Cell Res | 2004 | https://conductscience.org/library/papers/15149846 | PubMed |
| 12 | 38821619 | MRI Texture Analysis of Inguinal Lymph Node Metastasis in Vulvar Cancer - Associations With Histopathology. | Anticancer Res | 2024 | https://conductscience.org/library/papers/38821619 | PubMed |
| 13 | 28758928 | Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28758928 | PubMed |
| 14 | 37345182 | Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345182 | PubMed |
| 15 | 30687231 | Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER. | Front Endocrinol (Lausanne) | 2018 | https://conductscience.org/library/papers/30687231 | PubMed |
| 16 | 37415190 | Cancer-associated fibroblast-derived PAI-1 promotes lymphatic metastasis via the induction of EndoMT in lymphatic endothelial cells. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37415190 | PubMed |
| 17 | 33415130 | Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition. | Front Cardiovasc Med | 2020 | https://conductscience.org/library/papers/33415130 | PubMed |
| 18 | 33367928 | Crosstalk between YAP and TGFβ regulates SERPINE1 expression in mesenchymal lung cancer cells. | Int J Oncol | 2021 | https://conductscience.org/library/papers/33367928 | PubMed |
| 19 | 31072060 | GPCR-Hippo Signaling in Cancer. | Cells | 2019 | https://conductscience.org/library/papers/31072060 | PubMed |
| 20 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42379802 | Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells In Vitro. | In Vivo | 2026 | https://conductscience.org/library/papers/42379802 | PubMed |
| 42232322 | INHIBITING THE INHIBITOR: WOULD TARGETING PAI-1 RESULT IN A LOW-DOSE, WELL-TOLERATED TREATMENT OF EMPYEMA? | Biomed Sci Instrum | 2025 | https://conductscience.org/library/papers/42232322 | PubMed |
| 40280717 | Expression of "Hallmarks of Cancer" Genes in Cervical Carcinoma Is Differentially Affected by GPER1 Overexpression Depending on Histologic Entity. | Cancer Genomics Proteomics | 2025 | https://conductscience.org/library/papers/40280717 | PubMed |
| 40002669 | Constructing a Glioblastoma Prognostic Model Related to Fatty Acid Metabolism Using Machine Learning and Identifying F13A1 as a Potential Target. | Biomedicines | 2025 | https://conductscience.org/library/papers/40002669 | PubMed |
| 39738932 | Identification of a gene score related to antigen processing and presentation machinery for predicting prognosis in head and neck squamous cell carcinoma and its potential implications for immunotherapy. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39738932 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GPER1 | 2852 | PubTator's text mining | https://conductscience.org/library/genes/2852 | NCBI Gene |
| SERPINE1 | 5054 | PubTator's text mining | https://conductscience.org/library/genes/5054 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39467628
GET https://conductscience.org/api/papers/v1/39467628/references?page=2